KR20040029325A - ２-[５-(４-플루오로페닐)-３-피리딜메틸아미노메틸]-크로만및 이의 생리학적으로 허용가능한 염의 신규한 용도 - Google Patents
２-[５-(４-플루오로페닐)-３-피리딜메틸아미노메틸]-크로만및 이의 생리학적으로 허용가능한 염의 신규한 용도 Download PDFInfo
- Publication number
- KR20040029325A KR20040029325A KR10-2003-7016837A KR20037016837A KR20040029325A KR 20040029325 A KR20040029325 A KR 20040029325A KR 20037016837 A KR20037016837 A KR 20037016837A KR 20040029325 A KR20040029325 A KR 20040029325A
- Authority
- KR
- South Korea
- Prior art keywords
- fluorophenyl
- chroman
- syndrome
- parkinson
- physiologically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 200
- HKFMQJUJWSFOLY-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-2-yl)-n-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CNCC2OC3=CC=CC=C3CC2)=C1 HKFMQJUJWSFOLY-UHFFFAOYSA-N 0.000 title description 5
- 239000003814 drug Substances 0.000 claims abstract description 111
- 238000011282 treatment Methods 0.000 claims abstract description 97
- HKFMQJUJWSFOLY-NRFANRHFSA-N 1-[(2s)-3,4-dihydro-2h-chromen-2-yl]-n-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CNC[C@H]2OC3=CC=CC=C3CC2)=C1 HKFMQJUJWSFOLY-NRFANRHFSA-N 0.000 claims abstract description 77
- 230000000694 effects Effects 0.000 claims abstract description 50
- 238000004519 manufacturing process Methods 0.000 claims abstract description 39
- 208000019430 Motor disease Diseases 0.000 claims abstract description 20
- 206010034010 Parkinsonism Diseases 0.000 claims description 70
- 229940079593 drug Drugs 0.000 claims description 57
- 239000000939 antiparkinson agent Substances 0.000 claims description 47
- 230000000648 anti-parkinson Effects 0.000 claims description 43
- 208000012661 Dyskinesia Diseases 0.000 claims description 28
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 25
- 208000018737 Parkinson disease Diseases 0.000 claims description 25
- 206010044565 Tremor Diseases 0.000 claims description 22
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 21
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 19
- 206010008748 Chorea Diseases 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 208000002033 Myoclonus Diseases 0.000 claims description 12
- 208000016285 Movement disease Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 9
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 9
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 9
- 208000016620 Tourette disease Diseases 0.000 claims description 9
- 208000018839 Wilson disease Diseases 0.000 claims description 9
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 7
- 208000027776 Extrapyramidal disease Diseases 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 229960004205 carbidopa Drugs 0.000 claims description 4
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 4
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- QDLVYMYXOLGZOD-BOXHHOBZSA-N 1-[(2s)-3,4-dihydro-2h-chromen-2-yl]-n-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C1=CN=CC(CNC[C@H]2OC3=CC=CC=C3CC2)=C1 QDLVYMYXOLGZOD-BOXHHOBZSA-N 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 21
- 239000007788 liquid Substances 0.000 description 20
- 206010003591 Ataxia Diseases 0.000 description 16
- 241000700159 Rattus Species 0.000 description 14
- 238000010171 animal model Methods 0.000 description 13
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 13
- 208000011580 syndromic disease Diseases 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 208000023105 Huntington disease Diseases 0.000 description 9
- 208000012601 choreatic disease Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- 208000028017 Psychotic disease Diseases 0.000 description 8
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 8
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 241000282693 Cercopithecidae Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000001089 Multiple system atrophy Diseases 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 206010005159 blepharospasm Diseases 0.000 description 6
- 230000000744 blepharospasm Effects 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000003176 neuroleptic agent Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- WBLZUCOIBUDNBV-UHFFFAOYSA-N 3-nitropropanoic acid Chemical compound OC(=O)CC[N+]([O-])=O WBLZUCOIBUDNBV-UHFFFAOYSA-N 0.000 description 5
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229940035678 anti-parkinson drug Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 4
- 229960004170 clozapine Drugs 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 201000006517 essential tremor Diseases 0.000 description 4
- 229960003878 haloperidol Drugs 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 102000015554 Dopamine receptor Human genes 0.000 description 3
- 108050004812 Dopamine receptor Proteins 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 229960004046 apomorphine Drugs 0.000 description 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 3
- 230000000386 athletic effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940052760 dopamine agonists Drugs 0.000 description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000701 neuroleptic effect Effects 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QDLVYMYXOLGZOD-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-2-ylmethyl-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]azanium;chloride Chemical compound Cl.C1=CC(F)=CC=C1C1=CN=CC(CNCC2OC3=CC=CC=C3CC2)=C1 QDLVYMYXOLGZOD-UHFFFAOYSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010049816 Muscle tightness Diseases 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000024453 abnormal involuntary movement Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000001090 anti-dopaminergic effect Effects 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 208000021090 palsy Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000027714 reflex symptom Diseases 0.000 description 2
- -1 rofinirol Chemical compound 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- QMUJFXMVZVDRLD-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-2-yl)-2-[5-(4-fluorophenyl)pyridin-3-yl]ethanamine Chemical compound C1CC2=CC=CC=C2OC1C(N)CC(C=1)=CN=CC=1C1=CC=C(F)C=C1 QMUJFXMVZVDRLD-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 206010001540 Akathisia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 206010008027 Cerebellar atrophy Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 206010069917 Orthostatic tremor Diseases 0.000 description 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- KXEMQEGRZWUKJS-UHFFFAOYSA-N Raufloridine Natural products COC1=CC=C2C(CCN3CC4C(C)OC=C(C4CC33)C(=O)OC)=C3NC2=C1 KXEMQEGRZWUKJS-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002804 dopamine agent Substances 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004245 medial forebrain bundle Anatomy 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 230000002151 myoclonic effect Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003864 performance function Effects 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000003755 striatonigral degeneration Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01118097 | 2001-07-26 | ||
| EP01118097.3 | 2001-07-26 | ||
| PCT/EP2002/007660 WO2003009835A2 (en) | 2001-07-26 | 2002-07-10 | Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20040029325A true KR20040029325A (ko) | 2004-04-06 |
Family
ID=8178137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2003-7016837A Ceased KR20040029325A (ko) | 2001-07-26 | 2002-07-10 | ２-[５-(４-플루오로페닐)-３-피리딜메틸아미노메틸]-크로만및 이의 생리학적으로 허용가능한 염의 신규한 용도 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7872030B2 (https=) |
| EP (1) | EP1408964B1 (https=) |
| JP (1) | JP2004538289A (https=) |
| KR (1) | KR20040029325A (https=) |
| CN (1) | CN1292749C (https=) |
| AR (1) | AR037496A1 (https=) |
| AT (1) | ATE352302T1 (https=) |
| AU (1) | AU2002355170B2 (https=) |
| BR (1) | BR0211358A (https=) |
| CA (1) | CA2455621C (https=) |
| CY (1) | CY1107616T1 (https=) |
| DE (1) | DE60217870T2 (https=) |
| DK (1) | DK1408964T3 (https=) |
| ES (1) | ES2280602T3 (https=) |
| HU (1) | HUP0402092A3 (https=) |
| MX (1) | MXPA04000775A (https=) |
| MY (1) | MY134059A (https=) |
| PE (1) | PE20030277A1 (https=) |
| PL (1) | PL208258B1 (https=) |
| PT (1) | PT1408964E (https=) |
| RU (1) | RU2297833C2 (https=) |
| SI (1) | SI1408964T1 (https=) |
| WO (1) | WO2003009835A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1907382T3 (pl) | 2005-07-26 | 2016-01-29 | Bial Portela & Ca Sa | Pochodne nitrokatecholowe jako inhibitory COMT |
| EP1991677A2 (en) | 2006-01-26 | 2008-11-19 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| BRPI0721213B1 (pt) | 2007-01-31 | 2021-11-09 | Bial - Portela & Ca, S.A. | Uso de nitrocatecóis substituídos, e embalagem |
| WO2009116882A1 (en) | 2008-03-17 | 2009-09-24 | Portela & Ca., S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol |
| PT2413912T (pt) | 2009-04-01 | 2019-06-11 | Bial Portela & Ca Sa | Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir |
| NZ714887A (en) | 2009-09-11 | 2019-07-26 | Ionis Pharmaceuticals Inc | Modulation of huntingtin expression |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| JP6456143B2 (ja) | 2011-12-13 | 2019-01-23 | ノヴィファーマ，エス．アー． | カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物 |
| RU2017120184A (ru) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US576132A (en) * | 1897-02-02 | Current water-wheel | ||
| DE2364685C3 (de) | 1973-12-27 | 1978-06-15 | Beiersdorf Ag, 2000 Hamburg | Phenoxyäthylamine |
| US4438119A (en) * | 1982-12-23 | 1984-03-20 | Mead Johnson & Company | Method for alleviation of extrapyramidal motor disorders |
| CA1337429C (en) | 1983-12-05 | 1995-10-24 | Guy Rosalia Eugene Van Lommen | Derivatives of 2,2'-iminobisethanol |
| SE460947B (sv) * | 1986-08-26 | 1989-12-11 | Lejus Medical Ab | En multiple-unit-dos komposition av l-dopa |
| DE3901814A1 (de) * | 1988-07-28 | 1990-02-01 | Bayer Ag | Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga |
| ATE145208T1 (de) | 1990-07-06 | 1996-11-15 | Yoshitomi Pharmaceutical | Kondensierte thiophenverbindungen und deren verwendung |
| DE4135474A1 (de) * | 1991-10-28 | 1993-04-29 | Bayer Ag | 2-aminomethyl-chromane |
| US5314888A (en) * | 1992-02-21 | 1994-05-24 | Trustees Of Tufts College | Veterinary method for treating inappropriate elimination of urine in household pets |
| SI9300097B (en) | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
| JPH07507058A (ja) | 1992-03-11 | 1995-08-03 | インターニューロン ファーマシューティカルズ，インコーポレーテッド | 大型の中性アミノ酸（ｌｎａａ）の血中濃度の食後変動の低減 |
| DE4226527A1 (de) | 1992-08-11 | 1994-02-17 | Merck Patent Gmbh | 1,4-Benzodioxanderivate |
| GB9302622D0 (en) | 1993-02-10 | 1993-03-24 | Wellcome Found | Heteroaromatic compounds |
| WO1995020587A1 (en) * | 1994-01-31 | 1995-08-03 | Pfizer Inc. | Neuroprotective chroman compounds |
| IL114027A (en) | 1994-06-08 | 1999-11-30 | Lundbeck & Co As H | 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them |
| ATE210657T1 (de) * | 1994-10-14 | 2001-12-15 | Merck Patent Gmbh | Zns wirksames (r)-(-)-2-(5-(4-fluorophenyl)-3- pyridylmethylaminomethyl)chroman |
| US5502080A (en) * | 1994-11-01 | 1996-03-26 | Hitzig; Pietr | Combined use of dopamine and serotonin agonists in the treatment of allergic disorders |
| US5554383A (en) * | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
| US5541199A (en) * | 1995-06-02 | 1996-07-30 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| US6114334A (en) * | 1995-07-13 | 2000-09-05 | Knoll Aktiengesellschaft | Piperazine derivatives as therapeutic agents |
| GB9514380D0 (en) * | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
| US5670667A (en) * | 1995-07-25 | 1997-09-23 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| US5756521A (en) * | 1996-04-03 | 1998-05-26 | American Home Products Corporation | Chroman-2-ylmethylamino derivatives |
| DE19648384A1 (de) | 1996-11-22 | 1998-05-28 | Merck Patent Gmbh | Fluorene, Dibenzofurane und Dibenzothiophene |
| EP0900792B1 (en) | 1997-09-02 | 2003-10-29 | Duphar International Research B.V | Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists |
| ATE253058T1 (de) * | 1997-09-02 | 2003-11-15 | Duphar Int Res | Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten |
| DE19751949A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
| EP1061924A1 (en) | 1998-03-09 | 2000-12-27 | Trustees Of Tufts College | Treatment of compulsive behaviours in man and animals |
| EP1076647A2 (en) | 1998-04-29 | 2001-02-21 | American Home Products Corporation | Antipsychotic indolyl derivatives |
| UA71590C2 (en) | 1998-11-13 | 2004-12-15 | Duphar Int Res | Piperazine and piperidine derivatives |
| UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
-
2002
- 2002-07-10 PT PT02790172T patent/PT1408964E/pt unknown
- 2002-07-10 MX MXPA04000775A patent/MXPA04000775A/es active IP Right Grant
- 2002-07-10 RU RU2004105844/15A patent/RU2297833C2/ru not_active IP Right Cessation
- 2002-07-10 AU AU2002355170A patent/AU2002355170B2/en not_active Ceased
- 2002-07-10 BR BR0211358-9A patent/BR0211358A/pt not_active Application Discontinuation
- 2002-07-10 PL PL367291A patent/PL208258B1/pl not_active IP Right Cessation
- 2002-07-10 KR KR10-2003-7016837A patent/KR20040029325A/ko not_active Ceased
- 2002-07-10 CN CNB028146794A patent/CN1292749C/zh not_active Expired - Fee Related
- 2002-07-10 DK DK02790172T patent/DK1408964T3/da active
- 2002-07-10 WO PCT/EP2002/007660 patent/WO2003009835A2/en not_active Ceased
- 2002-07-10 CA CA2455621A patent/CA2455621C/en not_active Expired - Fee Related
- 2002-07-10 JP JP2003515228A patent/JP2004538289A/ja active Pending
- 2002-07-10 SI SI200230518T patent/SI1408964T1/sl unknown
- 2002-07-10 HU HU0402092A patent/HUP0402092A3/hu unknown
- 2002-07-10 US US10/484,697 patent/US7872030B2/en not_active Expired - Fee Related
- 2002-07-10 ES ES02790172T patent/ES2280602T3/es not_active Expired - Lifetime
- 2002-07-10 AT AT02790172T patent/ATE352302T1/de active
- 2002-07-10 EP EP02790172A patent/EP1408964B1/en not_active Expired - Lifetime
- 2002-07-10 DE DE60217870T patent/DE60217870T2/de not_active Expired - Lifetime
- 2002-07-22 MY MYPI20022758A patent/MY134059A/en unknown
- 2002-07-24 PE PE2002000652A patent/PE20030277A1/es not_active Application Discontinuation
- 2002-07-26 AR ARP020102823A patent/AR037496A1/es unknown
-
2007
- 2007-04-19 CY CY20071100526T patent/CY1107616T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE352302T1 (de) | 2007-02-15 |
| JP2004538289A (ja) | 2004-12-24 |
| CN1535150A (zh) | 2004-10-06 |
| US20040171645A1 (en) | 2004-09-02 |
| ES2280602T3 (es) | 2007-09-16 |
| WO2003009835A3 (en) | 2003-08-07 |
| EP1408964B1 (en) | 2007-01-24 |
| MY134059A (en) | 2007-11-30 |
| CA2455621C (en) | 2010-11-16 |
| SI1408964T1 (sl) | 2007-06-30 |
| AR037496A1 (es) | 2004-11-17 |
| WO2003009835A2 (en) | 2003-02-06 |
| CA2455621A1 (en) | 2003-02-06 |
| CY1107616T1 (el) | 2013-03-13 |
| CN1292749C (zh) | 2007-01-03 |
| EP1408964A2 (en) | 2004-04-21 |
| DK1408964T3 (da) | 2007-05-21 |
| BR0211358A (pt) | 2004-09-21 |
| HK1068793A1 (en) | 2005-07-29 |
| PL208258B1 (pl) | 2011-04-29 |
| US7872030B2 (en) | 2011-01-18 |
| DE60217870D1 (de) | 2007-03-15 |
| MXPA04000775A (es) | 2004-04-20 |
| PL367291A1 (en) | 2005-02-21 |
| AU2002355170B2 (en) | 2007-06-07 |
| HUP0402092A3 (en) | 2010-06-28 |
| RU2297833C2 (ru) | 2007-04-27 |
| DE60217870T2 (de) | 2007-11-15 |
| PE20030277A1 (es) | 2003-03-25 |
| PT1408964E (pt) | 2007-05-31 |
| HUP0402092A2 (hu) | 2005-02-28 |
| RU2004105844A (ru) | 2005-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20040029325A (ko) | ２-[５-(４-플루오로페닐)-３-피리딜메틸아미노메틸]-크로만및 이의 생리학적으로 허용가능한 염의 신규한 용도 | |
| JP4901046B2 (ja) | （ｒ）−（−）−２−［５−（４−フルオロフェニル）−３−ピリジルメチルアミノメチル］−クロマンおよびこの生理学的に許容し得る塩の新規な使用 | |
| AU2002355170A1 (en) | Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts | |
| AU2001230222A1 (en) | Novel use of (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]- chromane and its physiologically acceptable salts | |
| KR100886185B1 (ko) | 운동 장애의 치료 및 추체외로 운동 장애의 치료를 위해 투여된 약물에 의해 유도된 부작용의 치료를 위한 치환된 아미노메틸 크로만의 신규한 용도 | |
| PL208787B1 (pl) | (2R, 4R/S)-2-({[5-(4-fluorofenylo)-pirydyn-3ylmetylo)]-amino}-metylo)-chroman-4-ol i (2R, 4R)-2-({[5-(4-fluorofenylo)-pirydyn-3ylmetylo)]-amino}-metylo)-chroman-4-ol, sposoby ich otrzymywania i zastosowanie do wytwarzania preparatów medycznych oraz zawierająca je kompozycja farmaceutyczna | |
| AU2002331220A1 (en) | Novel use of substituted aminomethyl chromans for the treatment of movement disorder and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders | |
| ZA200401592B (en) | Novel use of 2-[5- (4-fluorophenyl)-3-pyridylmethylaminomethyl} -chromane and its physiologically acceptable salts | |
| HK1068793B (en) | Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl] and its physiologically acceptable salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20031224 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20070709 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20081113 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20090501 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20081113 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |